+Follow
TeckSoon
No personal profile
12
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
TeckSoon
2021-06-19
good
UPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3567581305992363","uuid":"3567581305992363","gmtCreate":1604566284889,"gmtModify":1604899384267,"name":"TeckSoon","pinyin":"tecksoon","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/6706c14aabf080276f5cf408a9896119","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":12,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":162943338,"gmtCreate":1624032633424,"gmtModify":1703827272561,"author":{"id":"3567581305992363","authorId":"3567581305992363","name":"TeckSoon","avatar":"https://static.tigerbbs.com/6706c14aabf080276f5cf408a9896119","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567581305992363","idStr":"3567581305992363"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162943338","repostId":"2144338772","repostType":2,"repost":{"id":"2144338772","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624031118,"share":"https://ttm.financial/m/news/2144338772?lang=en_US&edition=fundamental","pubTime":"2021-06-18 23:45","market":"us","language":"en","title":"UPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2144338772","media":"Reuters","summary":"(Adds details on offering, background) June 18 (Reuters) - Shares of Atai Life Sciences B.V. , bac","content":"<html><body><p>(Adds details on offering, background)</p><p> June 18 (Reuters) - Shares of Atai Life Sciences B.V.</p><p> , backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.</p><p> The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering <a href=\"https://laohu8.com/S/IPO.UK\">$(IPO.UK)$</a> on Thursday.</p><p> The company's shares opened at $21, compared with their IPO price of $15 apiece. </p><p> Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies.</p><p> Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. </p><p> Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter. </p><p> Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic. </p><p> Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering.</p><p> (Reporting by Sohini Podder and Niket Nishant in Bengaluru; Editing by Devika Syamnath)</p><p>((sohini.podder@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-18 23:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details on offering, background)</p><p> June 18 (Reuters) - Shares of Atai Life Sciences B.V.</p><p> , backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.</p><p> The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering <a href=\"https://laohu8.com/S/IPO.UK\">$(IPO.UK)$</a> on Thursday.</p><p> The company's shares opened at $21, compared with their IPO price of $15 apiece. </p><p> Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies.</p><p> Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. </p><p> Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter. </p><p> Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic. </p><p> Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering.</p><p> (Reporting by Sohini Podder and Niket Nishant in Bengaluru; Editing by Devika Syamnath)</p><p>((sohini.podder@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","QID":"两倍做空纳斯达克指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","PSQ":"做空纳斯达克100指数ETF-ProShares",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","ATAI":"Atai Beckley Inc","QQQ":"纳指100ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144338772","content_text":"(Adds details on offering, background) June 18 (Reuters) - Shares of Atai Life Sciences B.V. , backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion. The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering $(IPO.UK)$ on Thursday. The company's shares opened at $21, compared with their IPO price of $15 apiece. Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies. Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter. Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic. Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering. (Reporting by Sohini Podder and Niket Nishant in Bengaluru; Editing by Devika Syamnath)((sohini.podder@thomsonreuters.com;))","news_type":1,"symbols_score_info":{".IXIC":1,"MNQmain":0.6,"QQQ":0.6,"SQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"ATAI":0.9,"TQQQ":0.6,"NQmain":1,"NDAQ":1}},"isVote":1,"tweetType":1,"viewCount":732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":162943338,"gmtCreate":1624032633424,"gmtModify":1703827272561,"author":{"id":"3567581305992363","authorId":"3567581305992363","name":"TeckSoon","avatar":"https://static.tigerbbs.com/6706c14aabf080276f5cf408a9896119","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3567581305992363","idStr":"3567581305992363"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/162943338","repostId":"2144338772","repostType":2,"repost":{"id":"2144338772","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624031118,"share":"https://ttm.financial/m/news/2144338772?lang=en_US&edition=fundamental","pubTime":"2021-06-18 23:45","market":"us","language":"en","title":"UPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2144338772","media":"Reuters","summary":"(Adds details on offering, background) June 18 (Reuters) - Shares of Atai Life Sciences B.V. , bac","content":"<html><body><p>(Adds details on offering, background)</p><p> June 18 (Reuters) - Shares of Atai Life Sciences B.V.</p><p> , backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.</p><p> The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering <a href=\"https://laohu8.com/S/IPO.UK\">$(IPO.UK)$</a> on Thursday.</p><p> The company's shares opened at $21, compared with their IPO price of $15 apiece. </p><p> Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies.</p><p> Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. </p><p> Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter. </p><p> Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic. </p><p> Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering.</p><p> (Reporting by Sohini Podder and Niket Nishant in Bengaluru; Editing by Devika Syamnath)</p><p>((sohini.podder@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Thiel-backed psychedelics firm Atai valued at $3.19 bln in Nasdaq debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-18 23:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Adds details on offering, background)</p><p> June 18 (Reuters) - Shares of Atai Life Sciences B.V.</p><p> , backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion.</p><p> The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering <a href=\"https://laohu8.com/S/IPO.UK\">$(IPO.UK)$</a> on Thursday.</p><p> The company's shares opened at $21, compared with their IPO price of $15 apiece. </p><p> Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies.</p><p> Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. </p><p> Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter. </p><p> Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic. </p><p> Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering.</p><p> (Reporting by Sohini Podder and Niket Nishant in Bengaluru; Editing by Devika Syamnath)</p><p>((sohini.podder@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","QID":"两倍做空纳斯达克指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","PSQ":"做空纳斯达克100指数ETF-ProShares",".IXIC":"NASDAQ Composite","TQQQ":"纳指三倍做多ETF","ATAI":"Atai Beckley Inc","QQQ":"纳指100ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144338772","content_text":"(Adds details on offering, background) June 18 (Reuters) - Shares of Atai Life Sciences B.V. , backed by billionaire investor Peter Thiel, jumped 40% in their U.S. stock market debut on Friday, giving the German psychedelics startup a market capitalization of $3.19 billion. The Berlin-based biotech startup, which is exploring the use of psychedelic treatments for mental illnesses, raised $225 million from selling 15 million shares in its upsized initial public offering $(IPO.UK)$ on Thursday. The company's shares opened at $21, compared with their IPO price of $15 apiece. Atai was co-founded in 2018 by German investor Christian Angermayer, an advocate of the benefits of using psychedelics such as psilocybin to treat depression, anxiety and substance use disorders. The German startup has backed several companies developing such therapies. Psilocybin, the psychedelic active compound in magic mushrooms, was found to be at least as effective as escitalopram, a leading antidepressant drug, in a study by British scientists. Atai was considering floating its shares in the United States in May, Reuters reported in March, citing a source close to the matter. Its debut comes at a time when U.S. IPOs have already raised $171 billion in the first six months of the year, scorching past the 2020 record of $168 billion, according to data from Dealogic. Credit Suisse, Citigroup, Cowen and Berenberg were the lead underwriters for the offering. (Reporting by Sohini Podder and Niket Nishant in Bengaluru; Editing by Devika Syamnath)((sohini.podder@thomsonreuters.com;))","news_type":1,"symbols_score_info":{".IXIC":1,"MNQmain":0.6,"QQQ":0.6,"SQQQ":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"ATAI":0.9,"TQQQ":0.6,"NQmain":1,"NDAQ":1}},"isVote":1,"tweetType":1,"viewCount":732,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
